Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

First European Marketing Approval for SUMAVEL DosePro

December 2, 2010 6:19 am | News | Comments

Zogenix, Inc. and Desitin Pharmaceuticals GmbH announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application for SUMAVEL DosePro Needle-Free Delivery System.


Structural Prediction Software

December 1, 2010 8:21 am | Product Releases | Comments

Integrated DNA Technologies, a leader in oligonucleotide synthesis, and Rensselaer Polytechnic Institute announced the launch of the UNAFold secondary structure prediction software at IDT.


RAR-gamma Screening Kit

December 1, 2010 8:18 am | Product Releases | Comments

A robust, off-the-shelf solution for screening Human Retinoic Acid Receptor Gamma (RAR?) is now available from INDIGO Biosciences. INDIGO Nuclear Receptor Assay Kits go from freezer to data in 24 hours with minimal hands-on time.


Guide to Good Washing Practice

December 1, 2010 8:11 am | News | Comments

Thermo Fisher Scientific Inc. offers a ‘guide to good washing practice,’ an online guide is designed as a step-by-step tool, providing detailed guidance on obtaining secure and reliable performance with every use of the its Wellwash microplate washers.


HCS Plates

December 1, 2010 8:08 am | Drug Discovery & Development | Product Releases | Comments

CYTOO Cell Architects introduced CYTOOplates 96 for pharma, biotech and academic screening center customers employing high content cell-based assays for research, drug safety, and drug screening applications.


Aushon Partners with LightArray in China

December 1, 2010 8:06 am | News | Comments

Aushon BioSystems, Inc. has partnered with LightArray Biotech Company, Ltd., to provide Aushon’s suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.


Advanced Clinical Hires New VP

December 1, 2010 8:00 am | News | Comments

Advanced Clinical, a leader in pharmaceutical development, announced an addition to its leadership team: Mark Lanfear has been hired as Vice President, Clinical Operations to lead Advanced Clinical in its expansion of service offerings for 2011.


Optimer Submits Fidaxomicin NDA

December 1, 2010 7:50 am | News | Comments

Optimer Pharmaceuticals, Inc. announced that it has completed the submission of its new drug application to the U.S. Food and Drug Administration for fidaxomicin to treat patients with Clostridium difficile infection and to prevent recurrences of CDI.


Shire Announces Firazyr Trial Results

December 1, 2010 7:45 am | News | Comments

Shire plc announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase 3 trials studying the use of Firazyr for treatment of acute attacks of hereditary angioedema.


Celebrex May Ward Off Skin Cancers

December 1, 2010 7:23 am | News | Comments

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.


Reduced Enzyme Activity Heralds Alzheimer's Onset

December 1, 2010 7:21 am | News | Comments

A scientific report has found evidence of reduced activity of an energy-generating enzyme in deceased young adult brain donors who carry a common genetic risk factor for Alzheimer's disease.


Mutated HIV Lacks Immune Killing Power

December 1, 2010 7:17 am | News | Comments

Mayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves despite a lack of response to standard anti-retroviral treatment. In these cases, researchers say, the virus has lost its ability to kill immune cells.


Antimicrobials A Common Cause of Liver Injury

December 1, 2010 7:15 am | News | Comments

New research shows that anti-microbial medications are a common cause of drug-induced liver injury leading to acute liver failure, with women and minorities disproportionately affected.


FDA Approves Octapharma's IND

December 1, 2010 7:08 am | News | Comments

The U.S. Food and Drug Administration has approved Octapharma USA’s investigational new drug application for octaplex as a fast track product for reversing anticoagulation therapy in patients needing urgent Surgery or invasive procedures.


BioClinica Partners with Kaizen Clinical Services

December 1, 2010 7:02 am | News | Comments

BioClinica, Inc., a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncology-focused contract research organization.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.